Global Regenerative Medicines Market Report 2020-2030: 230+ Products and Services, 50 Brands, 350 Pipeline Products, 50+ Companies

DUBLIN, April 21, 2021 /PRNewswire/ -- The "Global Regenerative Medicines Market 2020-2030: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicines market is projected to reach $87.03 billion by 2030. The study also highlights that the market is set to witness a CAGR of 13.99% from 2020 and 2030.

The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.

Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.

This comprehensive study of the regenerative medicines market extensively covers the following:

• Market numbers on micro-segments that are influencing the market
• More than 230 products and services present in the market
• Over 50 brands
• More than 350 pipeline products
• Market share analysis for more than eight product segments
• Application information on more than six extensively employed applications
• Detailed global and regional market share analysis, including the scrutiny of more than 17 countries
• Study of data of more than 50 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 550+ products, services, and pipeline potential.

The study indicates increasing consolidation among healthcare juggernauts, a rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and an increasing awareness for stem cell therapeutics are fueling the growth of the global regenerative medicines market.

The market intelligence additionally throws a spotlight on the opportunities existing in the market, such as drug approvals and a strong pipeline of cell and gene therapies, multiple investments into building cGMP facilities, and innovations in regenerative medicine, among others.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include types of products and services, applications, and regions. The products and services segment and the region segments have been further sub-segmented to offer an in-depth analysis of the global regenerative medicines market.

The product and ecosystem analysis of the global market includes data analysis on the type of offerings available in the market. Pertaining to the market segmentation, the product segment is segmented broadly into tissue engineering products, stem cell products and services, and cell and gene therapy products. The tissue engineering segment has been further segmented into allogenic tissue, autologous tissue, xenogeneic tissue, synthetic tissue, and other tissue products. The stem cell products and services segment has been further segmented into stem cell services and stem cell therapeutics.

Further, cell and gene therapy has been segmented into cell therapy and gene therapy. The cell therapy segment has also been segmented into CAR-T therapies and other cell therapies.

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.

The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by the analyst also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Pharmaceutical companies looking to enter the cell and gene therapy market
• Manufacturers of regenerative medicine products such as tissue engineering products, attempting to understand short-term and long-term trends expected to influence market demand
• CDMOs and CMOs who are actively participating in the manufacture and scale-up of cell and gene therapies, worldwide
• Cell and gene therapy innovators looking forward to creating synergies with CDMOs and CMOs
• Emerging cell and gene therapy innovators attempting to understand the competitive landscape of the industry

How can market intelligence on regenerative medicines add value to an organization's decision-making process?

• Aid in product development
• Help in targeting a segment for launching a new product or service
• Offer go-to market access strategies
• Support in diversifying the product portfolio basis risk and progression of underlying technologies
• Help in analyzing specifications
• Aid in understanding the pipeline potential of emerging companies
• Gain holistic views pertaining to the regions and understand the market potential of the countries
• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies

Market Dynamics

Market Drivers

• Increasing Consolidation in the Regenerative Medicines Market
• Rising Number of Clinical Trials
• Favorable Regulatory Environment
• Rising Awareness for Stem Cell Therapeutics

Market Restraints

• Lack of Reliable Vector Production for Cell and Gene Therapy
• Exorbitant Cost of Next-Generation Therapies

Opportunities

• Drug Approvals and Strong Pipeline of Cell and Gene Therapies
• Multiple Investments in Expansion of cGMP Units
• Innovations in Regenerative Medicine

Companies Mentioned

• AbbVie, Inc.
• Baxter International Inc.
• Becton, Dickinson and Company
• Dendreon Pharmaceuticals LLC
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Holdings Corporation
• Gilead Sciences, Inc.
• Integra LifeSciences Holdings Corporation
• Johnson & Johnson
• Medtronic plc
• Mesoblast Ltd.
• Novartis International AG
• NuVasive, Inc.
• Organogenesis Holdings Inc.
• Smith & Nephew plc
• Stryker Corporation
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/sj39ob

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com